Drug Discovery & Synthesis of Contraceptive Agents
药物发现
基本信息
- 批准号:8550538
- 负责人:
- 金额:$ 84.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-24 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:ActinsAdverse effectsAgonistAnimal ExperimentsAnimal TestingAnimalsBindingBioavailableBiological AssayBiological AvailabilityBiological FactorsBundlingCalciumCationsChemicalsClinical TrialsCollaborationsContraceptive AgentsContraceptive methodsCouplesDevelopmentDrug DesignDrug KineticsEnzymesFemaleFemale ContraceptionsFemale Contraceptive AgentsFertilizationFundingGeneticGerm CellsGoalsGonadotropinsHealth SciencesHormonalHormonal Oral ContraceptivesHumanIn VitroInfertilityInstructionKansasKnock-outLeadMacacaMale ContraceptionsMale Contraceptive AgentsMale InfertilityMarketingMedical centerMenstrual cycleMethodsModelingMusNational Institute of Child Health and Human DevelopmentOocytesOralOregonPDE3A gene productPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhosphotransferasesPregnancyPrimatesProdrugsPropertyRXRRegulationResearchResearch PersonnelRodentSpecificitySperm MotilityStructureUniversitiesVesicleWaterWomanWorkanalogbasecontraceptive targetdesigndrug discoverydrug synthesishigh throughput screeningimprovedin vivoinhibitor/antagonistkinase inhibitorlarge scale productionmalemedical schoolsmennonhuman primatenoveloocyte maturationpreventprogramsretinoic acid receptor alphascaffoldscreeningsertoli cellsmall moleculesperm cellvirtual
项目摘要
Three male and two female contraceptive drug discovery projects will be pursued, using state-of-the-art
methods such as high throughput screening, structure-based drug design, and hit-to-lead optinnization by
medicinal chemistry: 1. H2-Gamendazole (H2-GMZ) and Analogues of Narciclasine (NAR) for Male
Contraception: The hypothesis of this project is that H2-GMZ and other small molecules such as NAR can
be developed as reversible non-hormonal anti-spermatogenic contraceptive agents that reversibly disrupt
eEFIA-actin bundling in Sertoli cells. 2. Retinoic Acid Receptor Alpha (RARalpha) as a Target for Male
Contraception: Knockout models of RARa (Rara"'") and animal experiments with a RAR pan-antagonist
have validated RARalpha as a viable target for establishing reversible male infertility. The discovery of an alpha-selective RAR antagonist with good oral bioavailability is expected to provide a male contraceptive agent that has fewer unwanted side effects than existing pan-antagonists. 3. CATSPER as a Target for Male Contraception: The Cation channel of Sperm (CatSper) is involved in the regulation of intracellular calcium, an important component required for the initiation of sperm hypermotility during mammalian fertilization. Our working hypothesis is that inhibitors of CatSper will reduce sperm hypermotility by preventing Ca2+ influx and rendering sperm unable to successfully penetrate and fertilize the oocyte. 4. WEE2 Kinase as a Target for Female Contraception: Knockdown of WEE2 prevents fertilization of mature primate oocytes, indicating that WEE2 represents a promising target for the development of non-hormonal, gamete-specific contraceptive for women. 5. PDE3A as a Target for Female Contraception: The principal catabolic enzyme in the oocyte is phosphodiesterase 3A (PDE3A). Pharmacologic inhibitors of PDE3A block oocyte maturation in many species, including primates. These observations have led to the hypothesis that a selective PDE3A inhibitor could be developed as a female contraceptive agent.
将利用最先进的技术,开展三个男性和两个女性避孕药物发现项目。
高通量筛选、基于结构的药物设计和领先选择等方法
药物化学:1。H2-格列吡唑(H2-GMZ)和Narciclasine(NAR)类似物用于男性
避孕:该项目的假设是,H2-GMZ和其他小分子如NAR可以
被开发为可逆的非激素抗生精避孕药,可逆地破坏
支持细胞中的eEFIA-肌动蛋白集束。2.视黄酸受体α(RAR α)作为男性的靶点
避孕:RAR α(Rara-1)的敲除模型和使用RAR泛拮抗剂的动物实验
已经验证了RAR α作为建立可逆性男性不育症的可行靶点。具有良好口服生物利用度的α-选择性RAR拮抗剂的发现预期提供比现有的泛拮抗剂具有更少的不希望的副作用的男性避孕剂。3. CATSPER作为男性避孕的靶点:精子阳离子通道(CatSper)参与细胞内钙的调节,细胞内钙是哺乳动物受精过程中启动精子运动过度所需的重要成分。我们的工作假设是CatSper抑制剂将通过阻止Ca 2+内流并使精子无法成功穿透卵母细胞并使其受精来降低精子运动过度。4. WEE 2激酶作为女性避孕的靶点:WEE 2的敲低可阻止成熟灵长类动物卵母细胞的受精,表明WEE 2代表了开发女性非激素、配子特异性避孕药的有希望的靶点。5. PDE 3A作为女性避孕的靶点:卵母细胞中的主要分解代谢酶是磷酸二酯酶3A(PDE 3A)。PDE 3A的药理学抑制剂在许多物种中阻断卵母细胞成熟,包括灵长类动物。这些观察结果导致了这样的假设,即选择性PDE 3A抑制剂可以被开发为女性避孕药。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gunda I. Georg其他文献
Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors
大环二氢吡啶类似物作为泛-BET BD2优先抑制剂
- DOI:
10.1016/j.ejmech.2025.117504 - 发表时间:
2025-06-05 - 期刊:
- 影响因子:5.900
- 作者:
Jiewei Jiang;Taimeng Liang;Jonathan Solberg;Alice Chan;Prakriti Kalra;Rui Shi;William C.K. Pomerantz;Jon E. Hawkinson;Ernst Schönbrunn;Gunda I. Georg - 通讯作者:
Gunda I. Georg
Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primates
使用 YCT-529 靶向视黄酸信号通路以在小鼠和灵长类动物中实现有效且可逆的口服避孕
- DOI:
10.1038/s43856-025-00752-7 - 发表时间:
2025-03-13 - 期刊:
- 影响因子:6.300
- 作者:
Nadja Mannowetz;Sanny S. W. Chung;Soma Maitra;Md Abdullah Al Noman;Henry L. Wong;Narsihmulu Cheryala;Akash Bakshi;Debra J. Wolgemuth;Gunda I. Georg - 通讯作者:
Gunda I. Georg
Development of the retinoic acid receptor alpha-specific antagonist YCT-529 for male contraception: A brief review
维甲酸受体α特异性拮抗剂YCT - 529用于男性避孕的研发:简要综述
- DOI:
10.1016/j.contraception.2024.110809 - 发表时间:
2025-05-01 - 期刊:
- 影响因子:2.300
- 作者:
Rui Shi;Debra J. Wolgemuth;Gunda I. Georg - 通讯作者:
Gunda I. Georg
Gunda I. Georg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gunda I. Georg', 18)}}的其他基金
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease
微生物合成治疗阿尔茨海默病的胆汁酸
- 批准号:
10602316 - 财政年份:2020
- 资助金额:
$ 84.14万 - 项目类别:
Core - Drug, Discovery, Design and Synthesis
核心 - 药物、发现、设计和合成
- 批准号:
8152937 - 财政年份:2010
- 资助金额:
$ 84.14万 - 项目类别:
Libraries for HTS: Privileged Structures in Sparsely Populated Chemical Space
HTS 库:稀疏化学空间中的特权结构
- 批准号:
7676007 - 财政年份:2007
- 资助金额:
$ 84.14万 - 项目类别:
Libraries for HTS: Privileged Structures in Sparsely Populated Chemical Space
HTS 库:稀疏化学空间中的特权结构
- 批准号:
7291334 - 财政年份:2007
- 资助金额:
$ 84.14万 - 项目类别:
Libraries for HTS: Privileged Structures in Sparsely Populated Chemical Space
HTS 库:稀疏化学空间中的特权结构
- 批准号:
7490019 - 财政年份:2007
- 资助金额:
$ 84.14万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 84.14万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 84.14万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 84.14万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 84.14万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 84.14万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 84.14万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 84.14万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 84.14万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 84.14万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 84.14万 - 项目类别:
Discovery Grants Program - Individual